Your browser doesn't support javascript.
loading
The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses.
Fisman, David; Giglio, Norberto; Levin, Myron J; Nguyen, Van Hung; Pelton, Stephen I; Postma, Maarten; Ruiz-Aragón, Jesús; Urueña, Analia; Mould-Quevedo, Joaquin F.
Afiliación
  • Fisman D; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Giglio N; Servicio de Consultorios Externos de Pediatría. Hospital de Niños Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina.
  • Levin MJ; Departments of Pedatrics and Medicine, University of Colorado School of Medicine, Denver, Colorado, United States.
  • Nguyen VH; VNH Consulting, Montreal, Québec, Canada.
  • Pelton SI; Department of Health Sciences, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Postma M; Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Ruiz-Aragón J; Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.
  • Urueña A; Faculty of Economics & Business, University of Groningen, Groningen, The Netherlands.
  • Mould-Quevedo JF; Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Hum Vaccin Immunother ; 20(1): 2351675, 2024 Dec 31.
Article en En | MEDLINE | ID: mdl-38835218
ABSTRACT
Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults <65 years of age, critically assesses the assumptions and approaches used in these analyses, and considers the role of cell-based influenza vaccines for children and adults. CEAs from multiple countries demonstrated the cost-effectiveness of cell-based quadrivalent influenza vaccines (QIVc) compared with egg-based trivalent/quadrivalent influenza vaccines (TIVe/QIVe). CEA findings were consistent across models relying on different relative vaccine effectiveness (rVE) estimate inputs, with the rVE of QIVc versus QIVe ranging from 8.1% to 36.2% in favor of QIVc. Across multiple scenarios and types of analyses, QIVc was consistently cost-effective compared with QIVe, including in children and adults across different regions of the world.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Análisis Costo-Beneficio / Gripe Humana Límite: Adolescent / Adult / Child / Child, preschool / Humans / Middle aged Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Análisis Costo-Beneficio / Gripe Humana Límite: Adolescent / Adult / Child / Child, preschool / Humans / Middle aged Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos